title: Quality of pathologic response and surgery correlate with survival for patients with completely resected bladder cancer after neoadjuvant chemotherapy.
abstract: BACKGROUND
  In a retrospective study of Southwestern Oncology Group (SWOG)-S8710/INT-0080 (radical cystectomy [RC] alone vs 3 cycles of neoadjuvant chemotherapy [NC] with methotrexate, vinblastine, doxorubicin, and cisplatin before RC for bladder cancer), factors found to be associated with improved overall survival (OS) included pathologic complete response, defined as P0; treatment with NC; completion of RC with negative surgical margins; and >or=10 pelvic lymph nodes (LNs) removed.
  
  
  METHODS
  The authors used stratified Cox regression to retrospectively study the association of quality of pathologic response after RC with OS in the subset of S8710 patients who received NC and RC with negative surgical margins.
  
  
  RESULTS
  Of 154 patients who received NC, 68 (44.2%) were <P2 (P0, Pa, P1, or carcinoma in situ [CIS]) at RC, 46 (29.9%) were P0, and the remainder had P2+ disease or did not undergo RC. In 115 patients who had RC with negative surgical margins, compared with P0 patients, those with residual Pa, P1, or CIS appeared to have worse OS (P=.054); OS was significantly worse for patients with residual P2+ disease (P=.0006). LN-positive (LN+) disease was found to be associated with worse OS than LN-negative (LN-) disease (P=.0005). Patients with LN- disease (ie, those with <10 LNs removed) appeared to have inferior OS compared with those with 10+ LNs removed (P=.079). The combination of pre-NC clinical stage and post-RC pathologic stage was found to be predictive of OS (P<.0001).
  
  
  CONCLUSIONS
  NC and RC with negative surgical margins for bladder cancer followed by pathologic P0 and LN- disease were found to correlate with improved OS. A combination of baseline clinical stage and post-RC pathologic stage may better predict OS.
authors.affiliation: Department of Medicine, Section of Medical Oncology, Baylor College of Medicine, Houston, Texas, USA. gurus@bcm.edu
authors.forename: Guru
authors.initials: G
authors.lastname: Sonpavde
authors.forename: Bryan H
authors.initials: BH
authors.lastname: Goldman
authors.forename: V O
authors.initials: VO
authors.lastname: Speights
authors.forename: Seth P
authors.initials: SP
authors.lastname: Lerner
authors.forename: David P
authors.initials: DP
authors.lastname: Wood
authors.forename: Nicholas J
authors.initials: NJ
authors.lastname: Vogelzang
authors.forename: Donald L
authors.initials: DL
authors.lastname: Trump
authors.forename: Ronald B
authors.initials: RB
authors.lastname: Natale
authors.forename: H Barton
authors.initials: HB
authors.lastname: Grossman
authors.forename: E David
authors.initials: ED
authors.lastname: Crawford
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D017024:Chemotherapy, Adjuvant; D002945:Cisplatin / Q000627:therapeutic use; D015653:Cystectomy; D004317:Doxorubicin / Q000627:therapeutic use; D006801:Humans; D008197:Lymph Node Excision; D008727:Methotrexate / Q000627:therapeutic use; D020360:Neoadjuvant Therapy; D011379:Prognosis; D012189:Retrospective Studies; D016019:Survival Analysis; D016896:Treatment Outcome; D001749:Urinary Bladder Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology / Q000601:surgery; D014747:Vinblastine / Q000627:therapeutic use
chemical_list: D014747:Vinblastine; D004317:Doxorubicin; D002945:Cisplatin; D008727:Methotrexate